Source: Annual Congress 2007 - Biology in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Leithner, E. Stacher, R. Wurm, F. Ploner, F. Quehenberger, J. Polachova, H. Samonigg, H. Popper, H. Olschewski (Graz, Austria). Trail receptors as prognostic factors in non-small cell lung cancer. Eur Respir J 2007; 30: Suppl. 51, 4242

Member's Comments

No comment yet.

Related content which might interest you: TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Source: Eur Respir J 2009; 33: 127-133 Year: 2009 Procalitonin: A prognosis factor in lung cancer and a marker for small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis Source: Eur Respir J 2016; 47: 1277-1280 Year: 2016 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 669s Year: 2007 Prognostic factors in non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Lung cancer Source: Respipedia Article Year: 2018 Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006